TYRA
$37.15-1.03 (-2.70%)
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÃ…P, a precision medicine platform that enables drug design th...
Recent News
This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position
This biotech firm develops targeted oncology therapies and leverages proprietary technology to address tumor resistance mechanisms.
Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet.
Relay Therapeutics develops precision oncology medicines using proprietary computational modeling and strategic industry partnerships.
Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit
Clinical-stage biotech Dianthus Therapeutics develops antibody therapies for severe autoimmune and neuromuscular conditions.
Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit
This Boston-based biotech develops therapies for neurological disorders, with a pipeline targeting depression, tremor, and rare epilepsies.
Did Deeper Losses and Dabogratinib Progress Just Shift Tyra Biosciences' (TYRA) Investment Narrative?
Tyra Biosciences reported a higher net loss for the fourth quarter and full year 2025, while simultaneously advancing its dabogratinib 3x3 clinical strategy and bolstering its leadership team. This combination of deeper losses and intensified late-stage development around dabogratinib in FGFR3-driven diseases is sharpening investor focus on the company’s precision oncology and rare disease ambitions. We will now examine how Tyra’s dabogratinib 3x3 strategy and recent clinical progress shape...